{
    "symbol": "THMO",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-12 10:18:01",
    "content": " As an integral part of this plan, we will leverage our proprietary high efficiency semi-automated CAR-TXpress platform, which has shown the ability to tangibly reduced processing time, improved cell recovery and potentially cut manufacturing costs associated with CAR-T and other cell gene therapy by up to 50%. Net revenues were $2.1 million for the quarter ended September 30, 2022 as compared to $3.2 million from the same quarter last year. Our gross profit for the quarter ended September 30, 2022 is 400,000 or 21% of that revenue, compared to $1.1 million or 35% of net revenue for the quarter ended September 30, 2021. For the quarter ended September 30, 2022, the company reported a net loss attributable to common stockholders of $3.2 million, or $0.10 per share, based on approximately $31.3 million shares outstanding. This compares to a net loss of $1.8 million or $0.15 per share based on approximately 11.9 million shares outstanding for the quarter ended September 30, 2021."
}